Protocol No.: M22-418

A Phase 3 Multicenter 24-Week Open Label Study to Evaluate the Safety, Tolerability, and Efficacy of Atogepant When Added to OnabotulinumtoxinA (BOTOX) for the Preventive Treatment of Chronic Migraine
Principal Investigator
Najib, Umer
Phase
III
Age Group
Adult
Applicable Disease Site
Headaches
Participating Institutions
Health Sciences Center
West Virginia University
Contact
Lauren Chase, RN
Clinical Research Specialist
Phone: +1 304-598-4000

View on ClinicalTrials.gov